
(hye drox’ ee proe jess’ ter own)
Makena
PREGNANCY CATEGORY B
Drug class
Progestin
Therapeutic Actions
Endogenous female hormone substance that inhibits spontaneous uterine contractions
Indications
Reduction of the risk of preterm birth in women with a singleton pregnancy and a history of singleton spontaneous preterm birth; not indicated for use in multiple gestations
Contraindications and Cautions
Contraindicated with known hypersensitivity to components of drug (hydroxyprogesterone, castor oil, benzyl benzoate, benzyl alcohol); history of thrombosis or thromboembolic disorders; known or suspected breast cancer or other hormone-sensitive cancer; undiagnosed abnormal vaginal bleeding; cholestatic jaundice of pregnancy; liver tumors, active liver disease; uncontrolled hypertension.
Use cautiously with prediabetic or diabetic states, pre-eclampsia, cardiac or renal dysfunction, clinical depression, lactation, seizure disorder.
Available Forms
Solution for injection—250 mg/mL
Dosages
Adults
250 mg IM once weekly, beginning between 16 wk, 0 days’ and 20 wk, 6 days’ gestation. Continue weekly injections until week 37 of gestation, or until delivery, whichever comes first.
Pediatric patients
Safety and efficacy not established.

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

